A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV (SMARTTT)
Tobacco Use Cessation
About this trial
This is an interventional treatment trial for Tobacco Use Cessation
Eligibility Criteria
Inclusion Criteria:
- HIV positive;
- >= 18 years old
- Receiving HIV care at Yale-New Haven Hospital, Mount Sinai Hospital, or SUNY Downstate STAR clinic;
- Have smoked >= 100 cigarettes in lifetime;
- Currently smokes some days or every day;
- Smokes, on average, >= 5 cigarettes per day;
- Able to provide written informed consent.
Exclusion Criteria:
- Using only non-cigarette nicotine products (i.e., e-cigs, Juul, etc.);
- Currently using NRT, VAR, or bupropion (defined as use in the prior 7 days);
- Self-report or urine testing confirming pregnancy, nursing, or trying to conceive;
- Life-threatening or unstable medical, surgical, or psychiatric condition;
- Inability to provide at least one collateral contact (family member or friend);
- Living out of state;
- Unable to read or understand English (except at Mount Sinai site).
Sites / Locations
- Yale University School of MedicineRecruiting
- SUNY Downstate STAR ClinicRecruiting
- Icahn School of Medicine at Mount SinaiRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
12 wks NRT+CM / 12 wks NRT+CM
12 wks NRT+CM/ 12 wks VAR or bupropion+CM
12 wks NRT+CM/12 wks NRT+CM plus
12 wks NRT/ 12 wks NRT
12 wks NRT/ 12 wks VAR or bupropion
12 wks NRT/ 12 wks NRT+CM
Nicotine replacement therapy combined with contingency management. Responders remain on same treatment for second 12 weeks.
Nicotine replacement therapy combined with contingency management. Non-responders switch to varenicline or bupropion combined with contingency management for second 12 weeks.
Nicotine replacement therapy combined with contingency management Non-responders switch to nicotine replacement therapy combined with intensified contingency management for second 12 weeks.
Nicotine replacement therapy alone. Responders remain on nicotine replacement therapy.
Nicotine replacement therapy alone. Non-responders switch to varenicline or bupropion alone for second 12 weeks.
Nicotine replacement therapy alone. Non-responders switch to nicotine replacement therapy combined with contingency management for second 12 weeks.